去纤软肝胶囊抗肝纤维化的实验与临床研究  

Inhibitory effect of Quxianruangan Capsulae on liver fibrosis in rats and chronic hepatitis patients

作　　者：杨晴[1] 颜迎春[1] 高彦欣[1] 

机构地区：[1]沈阳市第六人民医院传染科,辽宁省沈阳市110006

出　　处：《世界华人消化杂志》2001年第11期1246-1249,共4页World Chinese Journal of Digestology

摘　　要：目的研究中药去纤软肝胶囊的抗肝纤维化作用。方法用500mg·kg^(-1)CCL_4制备大鼠肝纤维化模型,将50只大鼠随机分为正常对照组(n=12),模型组(n=19)和治疗组(n=19-),治疗组投以去纤软肝胶囊治疗(2g·kg^(-1)·d^(-1))4wk,观察肝组织病理改变并对肝组织胶原纤维进行图象定量分析,检测血清明质酸(HA),层粘蛋白(LN),Ⅲ型前胶原(PcⅢ),Ⅳ型胶原(CIV)含量及ALT,Alb等肝功能指标;临床选择82例慢性乙肝及肝硬化随机分为治疗组(n=41)及常规对照组(n=41),以双盲法给药(12g·kg^(-1)·d^(-1)),治疗前及3mo后检测上述各项血清指标。结果与模型组比,治疗组大鼠肝组织纤维化程度减轻,胶原纤维含量减少(P<0.01),HA,LN,PcⅢ及CIV含量显著下降(μg·L^(-1);163.5±15.9,100.0±10.4,173.8±14.8,66.8±7.3;vs 199.4±14.3,118.9±14.9,199.8±12.3,83.3±8.7. P<0.01,P<0.05).ALT下降(nkat·L^(-1):1219.2±109.5,vs1405.8±162.0;P<0.01).Alb提升(g·L^(-1),28.3±1.1,vs26.6±0.7;P<0.05.).治疗后患者上述各项血清指标较对照组明显趋于正常(183.3±60.8,118.3±20.2,150.7±36.73,68.7±13.7,553.4±75.7,38.8±2.9;vs 331.3±172.3,145.9±32.9,191.9±46.7,92.9±23.4,743.2±302.4,36.4±2.8;P<0.01,P<0.05)。结论去纤软肝胶囊有一定的抗肝纤维化作用。AIM To Study the effect of Quxianruangan Capsulae in anti- hepetofibrosis. METHODS The heapatofibrosis model was induced by 500mg·kg^(-1) carbontetrachloride(CCL4) oily solution (with olive oil). Fifty rats were rand omly divided into three groups (untreated group:12; model group: 19; treatment group 19). The group was treated by Quxianruangan Capsulae. Liver tissue was studied with histopathlogical assay. The area of collagen was studied using color analysis system. Its serum levels of hyaluronic acid(HA), laminin(LN), typelV collagen(ClV) and typeⅢ precollagen (PCIII) and others were tested. Eighty-two chronic hepatitis B and chrrhosis of liver were selected. The patients were randomly divided into two group- treatment group(n=41) and routine group(n=41). The patients were tollowed up for 3 months. RESULTS In comparison with the model group, the degree of liver fibrosis of the rats group treated were lessened. The degree of the collagen fibrosis were reduced (P<0.01). The serum levels of hyaluroni acid (HA), leminin (LN), typelVcollagen (CIV) and type Ⅲ precollagen (PC Ⅲ) were markedly reduced (treatment group: μg·L^(-1) 163.5±15.9, 100.0±10.4, 173.8±14.8, 66.8 ±7.3; model group: 199.4±14.3, 118.9±14.9, 199.8±12. 3, 83.3±8.7(P<0.01, P<0.05). Alamine transaminase (AIt) was markedly reduced. White albumen were markedly increased(trsatment group: nkat·L^(-1) 1219.2± 109.5, g·L^(-1) 38.3±1.1; model group: 1405.8±16.2, 26.6± 0.7/; P<0.01, P<0.05). After 3 months of treatment, each index mantioned above became normal in comparison with routine group(treatment group: 183.3±60.8, 118.3± 20.2, 150.7±36.7, 68.7±13, 7, 553.4±75.7, 38.8±2.9; routine treated group:331.3±172.3, 145.9±32.9, 191.9±46. 7, 92.9±23.4, 743.2±302.4, 36.4±2.8; P<0.01,P<0.05). CONCLUSIONS Quxianruangan Capsulae has inhibitory effect in liver fibrosis.

关 键 词：肝硬化 实验性 中医药疗示 

分 类 号：R285.5[医药卫生—中药学]